Nature Methods

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Dienstag, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Lexogen Unveils LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit, Revolutionizing Single-Cell RNA Sequencing

Retrieved on: 
Dienstag, November 14, 2023
Nature, DNA, Gene, HD, Transcriptome, Genomics, Head, Small RNA, RNA-Seq, Gene expression, Messenger, Workflow, Nature Methods, A-DNA, RNA, Gene expression profiling, Vaccine

LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.

Key Points: 
  • LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.
  • The key to LUTHOR HD's exceptional sensitivity lies in its innovative THOR (T7 High-resolution Original RNA amplification) technology.
  • Lexogen's LUTHOR HD revolutionizes single-cell RNA sequencing, providing researchers with an unprecedented level of sensitivity, simplicity, and cost-efficiency.
  • Together with this product launch, Lexogen is proud to further characterize High-Definition Single-Cell RNA sequencing in November's edition of Nature Methods.

Lexogen Unveils LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit, Revolutionizing Single-Cell RNA Sequencing

Retrieved on: 
Dienstag, November 14, 2023
Nature, DNA, Gene, HD, Transcriptome, Genomics, Head, Small RNA, RNA-Seq, Gene expression, Messenger, Workflow, Nature Methods, A-DNA, RNA, Gene expression profiling, Vaccine

LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.

Key Points: 
  • LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.
  • The key to LUTHOR HD's exceptional sensitivity lies in its innovative THOR (T7 High-resolution Original RNA amplification) technology.
  • Lexogen's LUTHOR HD revolutionizes single-cell RNA sequencing, providing researchers with an unprecedented level of sensitivity, simplicity, and cost-efficiency.
  • Together with this product launch, Lexogen is proud to further characterize High-Definition Single-Cell RNA sequencing in November's edition of Nature Methods.

Lexogen's LUTHOR HD Application Note has been published in Nature: Advancing High-Definition Single-Cell RNA Sequencing

Retrieved on: 
Mittwoch, November 8, 2023
Gene, Nature Methods, Messenger, Medicine, Gene expression, Biology, RNA, Head, Vaccine, Nature

In this groundbreaking publication, Lexogen dives deep into the world of High-Definition Single-Cell RNA sequencing (scRNA-seq), shedding light on one of its latest products - the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit (LUTHOR HD).

Key Points: 
  • In this groundbreaking publication, Lexogen dives deep into the world of High-Definition Single-Cell RNA sequencing (scRNA-seq), shedding light on one of its latest products - the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit (LUTHOR HD).
  • LUTHOR HD represents a game-changing protocol that brings High-Definition single-cell RNA sequencing to the forefront.
  • A significant hurdle in single-cell RNA sequencing has been the detection of low-copy genes, which are crucial for understanding cellular function.
  • In the Nature Technical Application Note, Lexogen offers a detailed account of their cutting-edge scRNA-seq product's capabilities and applications.

Lexogen's LUTHOR HD Application Note has been published in Nature: Advancing High-Definition Single-Cell RNA Sequencing

Retrieved on: 
Mittwoch, November 8, 2023
Gene, Nature Methods, Messenger, Medicine, Gene expression, Biology, RNA, Head, Vaccine, Nature

In this groundbreaking publication, Lexogen dives deep into the world of High-Definition Single-Cell RNA sequencing (scRNA-seq), shedding light on one of its latest products - the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit (LUTHOR HD).

Key Points: 
  • In this groundbreaking publication, Lexogen dives deep into the world of High-Definition Single-Cell RNA sequencing (scRNA-seq), shedding light on one of its latest products - the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit (LUTHOR HD).
  • LUTHOR HD represents a game-changing protocol that brings High-Definition single-cell RNA sequencing to the forefront.
  • A significant hurdle in single-cell RNA sequencing has been the detection of low-copy genes, which are crucial for understanding cellular function.
  • In the Nature Technical Application Note, Lexogen offers a detailed account of their cutting-edge scRNA-seq product's capabilities and applications.

NIH Center for Alzheimer’s and Related Dementias publication shows comprehensive, high accuracy sequencing approach, using new Oxford Nanopore sequencing chemistry

Retrieved on: 
Dienstag, September 19, 2023
Research, Mental Health, Technology, Genetics, Health Technology, Software, Health, Data Management, Science, Oncology, CARD, Genetic variation, Methylation, Alcohol-related dementia, University, Nature Methods, Alzheimer's disease, Oxford, Dementia, Bangladesh Technical Education Board, SV, Chemistry, National Cancer Institute, Oxford Nanopore Technologies, HIV disease progression rates, R10, SNP, NIH, Genome, Disease, Fine chemical, Medical imaging, Antibiotics

The study protocol is currently being used to sequence thousands of brain-based human genomes as a part of the NIH CARD initiative.

Key Points: 
  • The study protocol is currently being used to sequence thousands of brain-based human genomes as a part of the NIH CARD initiative.
  • The methylation data is produced during a standard sequencing run and not as the result of a separate process.
  • Combined with the latest chemistry, Kit 14 and R10.4.1 flow cells, Oxford Nanopore now delivers the most complete and accurate genomic data, at scale.
  • “We are delighted to see this latest work from the NIH CARD team, whose approach demonstrates breakthrough accuracy with Oxford Nanopore’s newest Q20+ chemistry and the R10 nanopore, whilst using the same device.

The Best Thing Since Sliced Tissue

Retrieved on: 
Donnerstag, August 17, 2023
Engelhardt, Tissue, Nature Methods, Health, Stanford University, Neoplasm, 3D, GPSA, Ageing, Research, Medicine, Cell, Doctor of Philosophy, 2D, Protein, SAN, Diagnosis, William Ewart Gladstone, Gladstone Institutes, Gene, Bread, Medical imaging, List of things named after Carl Friedrich Gauss

SAN FRANCISCO, Aug. 17, 2023 /PRNewswire/ -- Imagine a few roughly cut slices of bread on a plate. With just those slices, could you picture, in fine detail, the loaf they came from?

Key Points: 
  • This approach, published in the journal Nature Methods, could allow for much deeper understanding of biological tissue samples.
  • This statistical approach harnesses data from the 2D tissue slices and, in the first layer, fits the warped 2D slice onto a 3D model of the tissue.
  • During this process, the GPSA model fills in the spaces between slices with predictions of gene or protein expression for every point throughout the tissue, ultimately generating a 3D "atlas" of the tissue.
  • In addition, when applied to slices taken from the same tissue at different points in time, GPSA can generate atlases that predict how every location within the tissue changes over time.

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

Retrieved on: 
Montag, Juni 26, 2023
NIST, Pan-genome, Genetic variation, Male, GeneDx, Associate professor, OPN1MW, Algorithm, Infertility, Genome, Harvard Medical School, National Institute of Standards and Technology, Biomarker, WGS, OPN1LW, Gene, DSM-IV codes, Dana–Farber Cancer Institute, Antibiotics, Nature Methods, Bottle

STAMFORD, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze.

Key Points: 
  • The analysis showcased the ability of the PGR-TK to access and interpret 395 challenging but medically relevant genes previously inaccessible.
  • "The PGR-TK implements a novel algorithm that reveals fine structures in complex segmental duplications.
  • This framework is scalable and enables analysis of multiple samples at varying resolution levels by adopting different parameters to facilitate exploratory analysis.
  • “They will also help us expand NIST's Genome in a Bottle benchmarks for understanding accuracy of methods in complex, medically relevant regions of the genome."

Eclipsebio Announces Publication of New Method to Optimize and Scale the Detection of RNA-Binding Protein Sites to Accelerate the Understanding of RNA Regulation

Retrieved on: 
Dienstag, Januar 17, 2023
Oncology, Health, Hospitals, Genetics, General Health, Pharmaceutical, Biotechnology, Eclipse, RBP, Immunoprecipitation, Disease, ABC, RT, RNA-binding protein, Amyotrophic lateral sclerosis, DNA, NASA eClips, University of California, San Diego, Protein, Therapy, Genomics, RNA, Research, Cancer, IP, UC, Vaccine, Television, Nature Methods

The study, published in Nature Methods , was led by Eclipsebio’s Associate Director of Research Daniel Lorenz, Ph.D., and co-founder Gene Yeo, Ph.D.

Key Points: 
  • The study, published in Nature Methods , was led by Eclipsebio’s Associate Director of Research Daniel Lorenz, Ph.D., and co-founder Gene Yeo, Ph.D.
  • Enhanced cross-linking immunoprecipitation followed by high-throughput sequencing, or eCLIP , is a powerful technique to uncover RNA sequences where RNA-binding proteins (RBPs) bind, known as RBP interactomes.
  • RBPs regulate RNA molecules, controlling the function and quantity of proteins expressed in a cell.
  • We look forward to supporting important RBP research with our current and future eCLIP products that will include the ABC technology.”

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"

Retrieved on: 
Freitag, Januar 13, 2023
Abraxis BioScience, Vertebrate Genomes Project, Genome, DNA methylation, DNA, Nature Methods, Economics, Genomics, Science, Chemistry, Doctor of Philosophy, High fidelity, Book

MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."

Key Points: 
  • MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."
  • "PacBio has led a transformation of genomics by making long-read sequencing more accurate and accessible than ever with the introduction of HiFi sequencing," said Christian Henry, President and Chief Executive Officer of PacBio.
  • "Nature Methods recognizes the criticality of highly accurate long-read sequencing to continuing to advance genomic research.
  • Nature Methods cited four wish-list items which further long-read sequencing: lower cost, greater accuracy, time savings, and increased application utility.